- Home
- ACLX
ACLX
Arcellx Inc.
as 05-30-2025 4:00pm EST
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 3.3B | IPO Year: | 2022 |
| Target Price: | $111.55 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $47.86 - $107.37 | Next Earning Date: | 05-08-2025 |
| Revenue: | $76,809,000 | Revenue Growth: | -41.66% |
| Revenue Growth (this year): | -33.05% | Revenue Growth (next year): | 119.90% |
Stock Insider Trading Activity of Arcellx Inc. (ACLX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Patel Kavita | ACLX | Director | May 20 '25 | Sell | $58.43 | 1,500 | $87,645.00 | 0 | |
| Patel Kavita | ACLX | Director | Apr 29 '25 | Sell | $64.20 | 1,500 | $96,300.00 | 0 | |
| Patel Kavita | ACLX | Director | Apr 8 '25 | Sell | $57.50 | 1,500 | $86,250.00 | 0 | |
| Patel Kavita | ACLX | Director | Mar 18 '25 | Sell | $71.64 | 1,500 | $107,460.00 | 0 |
Latest Arcellx Inc. News
ACLX Breaking Stock News: Dive into ACLX Ticker-Specific Updates for Smart Investing
Business Wire
11 days ago
Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025
Insider Monkey
12 days ago
Baron Discovery Fund Initiated a Position in Arcellx (ACLX)
MT Newswires
18 days ago
Arcellx's Potential Multiple Myeloma Treatment Shows 97% Overall Response Rate in Phase 2 Study; Shares Rise
Business Wire
18 days ago
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
Insider Monkey
20 days ago
Here’s Why Arcellx (ACLX) Declined in Q1
Simply Wall St.
22 days ago
Arcellx First Quarter 2025 Earnings: Misses Expectations
Zacks
24 days ago
Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates
Business Wire
24 days ago
Arcellx Provides First Quarter 2025 Financial Results and Business Highlights
Compare ACLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACLX Arcellx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.